Administration of coumarin, butylated hydroxyanisole and ethoxyquine for the treatment of canities
US8969407B2 · kind B2 · utility
0Cited by
9References
7Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 30, 2012 |
| Grant date | Mar 3, 2015 |
| Priority date | — |
| Expiry date | Nov 30, 2032 |
Classification
- Technology area (CPC H)Electricity
- CPC primaryH01L2924/0002
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
At least one compound selected from among coumarin and/or derivative thereof, butylated hydroxyanisole, ethoxyquine and mixtures thereof, and admixtures thereof with other active agents selected from among active agents for combating desquamative conditions of the scalp, plant extracts having propigmenting activity and active agents that slow hair loss and/or promote hair regrowth, are useful for preventing and/or limiting and/or stopping the development of canities.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.